公司于近日参与了"湖北省县域医共体设备标准化和提质升级项目"的投标， 招标单位为湖北省卫生健康委员会。2025 年 5 月 27 日，中国政府采购网（http s://www.ccgp.gov.cn）发布了相关中标结果公告。现将具体预中标情况提示如 下： 证券代码：301235 证券简称：华康洁净 公告编号：2025-065 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示：本项目仍处于中标公示阶段，其获取中标通知书、签约等后续工 作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应的信 息披露义务。 一、预中标项目概况 1、采购人名称：湖北省卫生健康委员会 2、采购代理机构名称：湖北省成套招标股份有限公司 3、中标名称：湖北省县域医共体设备标准化和提质升级项目二标包 二、预中标事项对公司业绩的影响 该项目为医疗设备采购业务，中标后的实施预计对公司未来经营业绩产生 ...

华康洁净（301235）公告，公司收到中标通知书，与中元建设集团组成的联合体中标"嘉兴市第二医院 整体迁建项目净化及实验室工程"，中标金额为1.67亿元。公司预计份额为1.33亿元，占公司2024年度经 审计营业收入的7.81%。项目总建筑面积46.13万平方米，最高洁净等级为百级，工期为260个日历天。 ...

1、建设规模：新建 17 层主体医疗楼，7 层行政科教楼及与它们连通的 2 层 地下室；新建污水处理站、垃圾处理站、液氧站等。同步实施道路广场、绿化、 室外管线等室外工程，设置机动车停车位 4,059 个；设置床位数 2,000 床。总建 筑面积 461,323.20 平方米，其中地上建筑面积 279,071.28 平方米，地下建筑面 积 182,251.92 平方米。本次净化及实验室的面积约为 25,265 平方米，最高洁净 等级为百级。 武汉华康世纪洁净科技股份有限公司 关于收到中标通知书的公告 | | | 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日在创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于 项目预中标的提示性公告》（公告编号：2025-049）。近日，公司收到招标代理 机构嘉兴市建新工程造价咨询事务所有限公司发出的《中标通知书》，确认公司 与中元建设集团股份有限公司组成的联合体（以下简称"联合体"）为"嘉兴市 第二医院整体迁建(长三角国际医学中心总医院)项目(主体医疗楼、行政科教楼、 2 号地下室、2 号地下污水处理站、 ...

Investment Rating - The report initiates coverage with a "Neutral" rating for the company [3][4]. Core Insights - The company is a professional cleanroom system integration service provider, expanding its business from public hospital medical cleanrooms to high-level academic laboratories and industrial electronics [3][13]. - The cleanroom market in China is expected to exceed 500 billion yuan by 2032, with a compound annual growth rate (CAGR) of over 7% from 2023 to 2032 [31][36]. - The company has a strong position in the cleanroom industry, with a focus on electronic cleanrooms expected to become a significant growth driver [5][30]. Summary by Sections Company Overview - The company provides full-cycle services for cleanroom construction, including project consulting, planning, design, management, construction, system debugging, and maintenance [3][19]. Financial Performance - The company has maintained steady revenue growth, with a CAGR of 23.8% from 2017 to 2024, although profits have faced some pressure due to delayed payments [25][28]. - Revenue projections for 2024 to 2027 show significant growth, with expected revenues of 1,708 million yuan in 2024, increasing to 4,151 million yuan by 2027 [6][18]. Market Potential - The electronic cleanroom sector is anticipated to be the fastest-growing segment for the company, with the market size expected to reach 165.7 billion yuan in 2024 [31][39]. - The company is positioned in the first tier of the industry, with a strong competitive advantage due to its technical capabilities and marketing network [30][42]. Technological Advantages - The company has developed various core technologies in cleanroom systems, enhancing its ability to attract customers and expand into new application scenarios [51][52]. - The company has accumulated numerous patents in the cleanroom field, indicating a strong focus on innovation and technology development [52]. Government Relations and Order Acquisition - The company has established strong relationships with government entities, enhancing its order acquisition capabilities, particularly in the electronic cleanroom sector [53].

Market Performance - On May 23, major market indices experienced fluctuations and closed lower, with A-shares trading volume reaching 1.18 trillion yuan, and over 1,100 stocks closing higher, including 52 stocks hitting the daily limit [1] - For the week, the Shanghai Composite Index fell by 0.57%, the ChiNext Index dropped by 0.88%, and the STAR Market 50 Index decreased by 1.47% [1] Individual Stock Performance - Over 1,600 stocks rose this week, with 22 stocks gaining over 30%. Notably, six stocks surged over 50%, with the largest increase being 99.96% for Sanofi [1][2] - Other significant gainers included Huibo Yuntong (301316) and Binhai Energy (000695), both of which saw weekly increases exceeding 60% [1][2] Sector Analysis - Among the stocks that rose over 30%, the pharmaceutical and biological sector had six representatives, followed by light industry manufacturing with three stocks [1] Historical Highs - On May 23, 17 stocks reached historical closing highs, with the pharmaceutical and biological, mechanical equipment, and automotive sectors showing a concentration of high performers [3][4] - The average increase for stocks reaching historical highs was 8.20%, with notable gainers including Xintiandi (301277) and Zhongzhou Special Materials (300963) [3] Institutional Activity - On May 23, ten stocks saw net purchases from institutions, with Yixin Tang (002727) leading at a net buy of 102 million yuan [5][6] - Conversely, institutions sold off stocks such as Hongchuang Holdings (002379) and Tianqimo (002510), each experiencing net sales exceeding 50 million yuan [5][6] Northbound Capital Flow - Northbound capital was present in nine stocks on the trading board, with net purchases in three stocks: Xue Ren Shares (002639), Huibo Yuntong, and Jinlongyu (002882) [7] - Yixin Tang faced the highest net sell-off from northbound capital, totaling 68.98 million yuan [7] Company Announcements - Zhongjin Gold (600489) plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues [8] - Huakang Clean (301235) won a bid for a healthcare project with a contract value of 60.24 million yuan and a duration of 120 days [8] - Weier Shares (603501) intends to issue H-shares and list on the Hong Kong Stock Exchange [9] - Yunchongma (603130) plans to raise no more than 640 million yuan for a project to produce DTY silk and high-performance leather base fabric [9]

Core Viewpoint - The company, originally established in 2008 as a leading cleanroom system integrator, is expanding its business from medical applications to laboratory integration and electronic cleanroom services, aiming to create a second growth curve and enhance its market position in the semiconductor ecosystem [1][2]. Group 1: Business Expansion and Market Position - The company has transitioned from focusing solely on medical cleanrooms to include laboratory integration and electronic cleanroom services, having served over 800 clients including public hospitals and industrial electronics firms [1]. - The company announced a name change from "Huakang Medical" to "Huakang Clean" in March 2025, and plans to issue 750 million yuan in convertible bonds to support new business initiatives [1]. - A joint venture named "Wuhan Guanggu Huafeng Operation Technology Co., Ltd." was established with partners to strengthen future growth in the cleanroom technology sector [1]. Group 2: Market Dynamics and Financial Performance - The medical purification system market in China is valued at approximately 31.27 billion yuan annually, with the company holding orders worth 2.753 billion yuan for 2024, indicating a robust order book [2]. - The company has achieved positive operating cash flow of 150 million yuan in 2024, indicating a balance between orders and cash flow, which supports sustainable growth in its core business [2]. - The electronic cleanroom sector, which accounted for 54% of the cleanroom industry in 2022, is expected to see continued demand growth, with the company entering this market through strategic partnerships and service capabilities [2]. Group 3: Revenue and Profit Forecast - Revenue projections for the company from 2025 to 2027 are estimated at 2.8 billion, 3.6 billion, and 4.8 billion yuan, representing year-on-year growth rates of 61%, 32%, and 33% respectively [3]. - The net profit attributable to the parent company is forecasted to be 170 million, 220 million, and 300 million yuan for the same period, with growth rates of 156%, 30%, and 35% respectively [3]. - The company is expected to maintain a solid growth trajectory based on its established experience in the medical cleanroom sector and its expansion into the semiconductor cleanroom market [3].

Investment Rating - The report gives a "Buy" rating for the company, Huakang Clean [5]. Core Views - Huakang Clean is a leading cleanroom system integrator in the medical sector, expanding into the electronic cleanroom market, which is experiencing high demand [3][5]. - The company has a solid order backlog in the medical sector, with a total order value of 2.753 billion yuan for 2024, indicating stable growth prospects [4][5]. - The electronic cleanroom segment is expected to become a significant growth driver, with the market for electronic cleanrooms projected to exceed 1 trillion yuan in 2022 [5][6]. Summary by Sections Company Overview - Established in 2008, Huakang Clean has evolved from a medical cleanroom service provider to include laboratory integration and electronic cleanroom services, serving over 800 clients [3][4]. - The company rebranded from "Huakang Medical" to "Huakang Clean" in March 2025 to better reflect its focus on clean technology [3]. Market Potential - The cleanroom market in China is projected to reach approximately 312.68 billion yuan annually, driven by the increasing demand for clean surgical rooms and system upgrades [4][48]. - The electronic cleanroom market, which accounted for 54% of the cleanroom industry in 2022, is expected to see continued growth due to rising semiconductor investments [5][56]. Financial Projections - Revenue forecasts for Huakang Clean are 2.755 billion yuan in 2025, 3.644 billion yuan in 2026, and 4.830 billion yuan in 2027, with expected growth rates of 61%, 32%, and 33% respectively [5][7]. - The net profit is projected to reach 171 million yuan in 2025, 222 million yuan in 2026, and 301 million yuan in 2027, reflecting growth rates of 156%, 30%, and 35% respectively [5][7]. Competitive Position - Huakang Clean holds a strong competitive position in the medical cleanroom sector, ranking among the top three in terms of bid amounts from 2017 to 2020 [48]. - The company has established a robust reputation and project experience, which enhances its ability to secure new contracts and expand its market share [71][79].

证券代码：301235 证券简称：华康洁净 公告编号：2025-063 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 4、中标单位：武汉华康世纪洁净科技股份有限公司 5、中标价格：60,239,413.05 元 6、工期：120 日历天 7、公示媒体：枣庄市公共资源交易中心（http://ggzy.zaozhuang.gov.cn） 8、公示期：2025 年 05 月 23 日至 2025 年 05 月 25 日 特别提示：本项目仍处于中标公示阶段，其获取中标通知书、签约等后续工 作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应的信 息披露义务。 公司于近日参与了"滕州市医养结合健康中心暨中心人民医院新院区项目共 享医疗综合楼特殊科室专项净化工程二标段"项目的投标，招标单位为山东德辰 康养投资管理有限公司。2025 年 5 月 23 日，枣庄市公共资源交易中心（ht ...

1、调整前回购股份价格上限：28.00 元/股（含）； | 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 关于2024年年度权益分派实施后调整回购股份价格上限 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 自本次利润分配预案披露之日起至权益分派股权登记日期间，公司总股本若因新 增股份上市、股权激励行权、股份回购等事项发生变化，公司将按照"现金分红总额 固定不变"的原则对分配比例进行调整。 公司 2024 年度权益分派股权登记日为 2025 年 5 月 28 日，除权除息日为 2025 年 5 月 29 日。具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn） 的《2024 年年度权益分派实施公告》（公告编号：2025-060）。 2、调整后回购股份价格上限：27.95 元/股（含）； 3、回购股份价格上限调整生效日期：2025 年 5 ...

证券代码：301235 证券简称：华康洁净 公告编号：2025-060 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 特别提示： 1、武汉华康世纪洁净科技股份有限公司（以下简称"公司"或"本公司"）通过 回购专用证券账户持有的公司股份 2,132,100 股不享有利润分配权利。因此，本次权 益分派将以公司现有总股本 105,600,000 股剔除已回购股份 2,132,100 股后的 103,467,900 股为基数，本次实际分红总额=实际参与现金分红的股本×分配比例 =103,467,900 股×0.5 元/10 股=5,173,395 元。 2、本次权益分派实施后，根据股票市值不变原则，实施权益分派前后公司总股本 保持不变。按照公司总股本折算每 10 股现金分红=本次实际现金分红总额/公司总股 本(含已回购股份)×10=5,173,395 元/105,600,000 股×10=0.489904 元(保留六位小 数，最后一位直接截取，不四舍五入)。本次权益分派实施后的除息除权参考价=除息 除权日前一交易日收盘价-按公司总股本折算每股现金分红=除息除权日前一交易日 收盘价-0. ...